In this video summary, Professor Stephan Weidinger, Germany, Professor Emma Guttman-Yassky, USA and Professor Adam Friedman, USA discuss the latest scientific knowledge in type 2 inflammation and its role in pathophysiology of atopic dermatitis (AD), how Dupixent addresses the disease process and provides efficacy across different phenotypes and the increasing real-world evidence for Dupixent in disease control in AD patients.